Stearns M E, Tew K D
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111.
J Cell Sci. 1988 Mar;89 ( Pt 3):331-42. doi: 10.1242/jcs.89.3.331.
We have investigated the ability of estramustine to bind to rat brain microtubule-associated proteins (MAPs) and purified MAP-2 in vitro. [3H]estramustine's relative affinity for tubulin and MAPs was assessed by gel filtration chromatography, immunoprecipitation and binding assays. Scatchard analysis demonstrated a specific affinity of the drug for MAP-2. Calculations from kinetic parameters and non-linear regression analysis gave a Kd of 15 microM, and a Bmax of 3.4 x 10(-7)M ml-1. Extrapolation of this value suggested that each MAP-2 molecule binds approximately 20 molecules of estramustine. Microtubule assembly studies and SDS-polyacrylamide gel electrophoresis revealed that at 20-60 microM levels, estramustine inhibited the association of MAPs with taxol microtubules. Turbidity (A350) studies further demonstrated that 20-60 microM-estramustine inhibited MAP-2-driven tubulin assembly and produced microtubule disassembly. Electron-microscopic studies confirmed the centrifugation and turbidity results. The data demonstrated that estramustine can bind MAPs and MAP-2 specifically, thereby inhibiting microtubule assembly.
我们已经研究了雌莫司汀在体外与大鼠脑微管相关蛋白(MAPs)及纯化的MAP - 2结合的能力。通过凝胶过滤色谱法、免疫沉淀法和结合试验评估了[³H]雌莫司汀对微管蛋白和MAPs的相对亲和力。Scatchard分析表明该药物对MAP - 2具有特异性亲和力。根据动力学参数计算和非线性回归分析得出解离常数(Kd)为15微摩尔,最大结合容量(Bmax)为3.4×10⁻⁷摩尔/毫升。外推该值表明每个MAP - 2分子大约结合20个雌莫司汀分子。微管组装研究和十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳显示,在20 - 60微摩尔浓度水平时,雌莫司汀抑制MAPs与紫杉醇微管的结合。比浊度(A350)研究进一步表明,20 - 60微摩尔的雌莫司汀抑制MAP - 2驱动的微管蛋白组装并导致微管解聚。电子显微镜研究证实了离心和比浊度结果。数据表明,雌莫司汀可特异性结合MAPs和MAP - 2,从而抑制微管组装。